KRYS News and Press, Krystal Biotech Inc. From 06/12/20

Quick Take Krystal Biotech (KRYS) has been developing game-changing, innovative topical gene therapies for serious diseases. Krystal went public in 2017 at around $10 a share and, currently, trades in the mid-forties and has a market cap close to $850 million. A legal ruling against Krysta...

PITTSBURGH, June 08, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Krish S. Krishnan, chairman...

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has priced the previo...

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has commenced an unde...

KB105 was well tolerated with no adverse events or immune response following redosing Clearly detectable TGM-1 expression in all treated areas following initial and repeat administration. KB105-expressed TGM1 was correctly localized in the epidermis, co-localizing with loricrin, and w...

Krystal Biotech (NASDAQ: KRYS ) files an automatic shelf registration statement with the SEC. More news on: Krystal Biotech, Inc., Healthcare stocks news, Read more ...

Krystal Biotech (NASDAQ: KRYS ): Q1 GAAP EPS of -$0.31 beats by $0.13 . Cash, cash equivalents and short-term investments of $186.7M. Press Release More news on: Krystal Biotech, Inc., Earnings news and commentary, Healthcare stocks news,

KB105 interim Phase 1/2 clinical data for treatment of autosomal recessive congenital ichthyosis (ARCI) to be announced at the Society for Investigative Dermatology (SID) Annual Meeting in May 2020 B-VEC Phase 3 pivotal study anticipated to start in 1H 2020 B-VEC Phase 1/2 clinical...

Internationally renowned ophthalmologist, Gerd Auffarth, MD, ranked as one of the “100 most influential personalities in ophthalmology worldwide" in the 2020 Power List published by The Ophthalmologist  magazine Julian Gangolli, former President of the North American...

Shares of Krystal Biotech (KRYS) have risen by over 200% since my July 2018 article recommended readers accumulate shares based on optimism for the gene therapy pioneer's STAR-D platform and its potential to address multiple rare skin diseases. On the other hand, performance is only slightly...